Cumberland Pharmaceuticals vs Sunshine Biopharma
Cumberland Pharmaceuticals is the larger business, with $44.5m of revenue in fiscal 2025 against $36.3m for Sunshine Biopharma (1.2 times as much). Cumberland Pharmaceuticals grew faster (17.6% against 4.1%). Cumberland Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -6.4% against -16.5%. Sunshine Biopharma carries less debt relative to equity (0.0% against 21.1%).
| Latest fiscal year | Cumberland PharmaceuticalsCPIX, 2025 | Sunshine BiopharmaSBFM, 2025 |
|---|---|---|
| Revenue | $44.5m | $36.3m |
| Revenue growth | 17.6% | 4.1% |
| Net income | −$2.8m | −$6.0m |
| Operating margin | -6.3% | -17.2% |
| Net margin | -6.4% | -16.5% |
| Return on equity | -11.9% | -25.7% |
| Free cash flow | $4.8m | −$5.5m |
| Cash | $11.4m | $9.1m |
| Total debt | $5.2m | $0 |
| Debt to equity | 21.1% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $263,478 | $0 |
| Employees | 93 | 50 |
| Market value | $64.4m | $6.5m |
| Price vs our value range | Above our value range | — |
| Moat score | 57 (Moderate) | 15 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |